http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8652520-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7d343de749196c42f9699b26456fa04 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24 |
| filingDate | 2012-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0040a0e163168cf3aead4c43b108b429 |
| publicationDate | 2014-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8652520-B2 |
| titleOfInvention | Combination tablet with chewable outer layer |
| abstract | A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10398712-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013091758-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10645923-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018125053-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11013751-B2 |
| priorityDate | 2007-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 260.